SCHEMBL4908685

SCHEMBL4908685

CCCCCCCc1ccc(-c2ccc(Br)cc2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.61
TSHR P16473 1/20 0.61
RARB P10826 7/20 0.59
ALDH1A1 P00352 3/20 0.59
RARA P10276 2/20 0.59
MEN1 O00255 2/20 0.59
MAPT P10636 2/20 0.59
KMT2A Q03164 2/20 0.59
MTOR P42345 1/20 0.59
ESR1 P03372 2/20 0.57
ADRA2A P08913 2/20 0.57
ADORA3 P0DMS8 2/20 0.57
TACR2 P21452 2/20 0.57
SLC6A2 P23975 2/20 0.57
SLC6A4 P31645 2/20 0.57
SLC6A3 Q01959 2/20 0.57
KDM4E B2RXH2 2/20 0.57
LMNA P02545 2/20 0.57
SHBG P04278 1/20 0.57
TP53 P04637 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10528231 1.00 HSD17B10 (0.61) HSD17B10TSHRRARBALDH1A1RARA
SCHEMBL8607022 1.00 HSD17B10 (0.61) HSD17B10TSHRRARBALDH1A1RARA
SCHEMBL26226733 1.00 HSD17B10 (0.61) HSD17B10TSHRRARBALDH1A1RARA
SCHEMBL10455067 1.00 HSD17B10 (0.61) HSD17B10TSHRRARBALDH1A1RARA
SCHEMBL31270913 1.00 HSD17B10 (0.61) HSD17B10TSHRRARBALDH1A1RARA
SCHEMBL22989786 1.00 HSD17B10 (0.61) HSD17B10TSHRRARBALDH1A1RARA
SCHEMBL1599747 0.98 RARB (0.58) HSD17B10TSHRRARBALDH1A1RARA
SCHEMBL15353198 0.94 ESR1 (0.63) HSD17B10TSHRALDH1A1ESR1ADRA2A
SCHEMBL340275 0.94 ESR1 (0.63) HSD17B10TSHRALDH1A1ESR1ADRA2A
SCHEMBL4191545 0.94 ESR1 (0.63) HSD17B10TSHRALDH1A1ESR1ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118834546-A Electrochromic device and preparation method thereof 吉林大学 2024-10-25 CN disclosed
CN-115745833-B Preparation method of 4-alkyl-4' -cyanobiphenyl 宁夏中星显示材料有限公司 2024-07-05 CN disclosed
CN-115745833-A Preparation method of 4-alkyl-4' -cyanobiphenyl 宁夏中星显示材料有限公司 2023-03-07 CN disclosed
US-20080015223-A1 Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto ARENA PHARMACEUTICALS, INC. (US) 2008-01-17 US disclosed
WO-2006060762-A2 PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2006-06-08 WO disclosed
US-6605323-B1 Monostable ferroelectric active matrix display AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) 2003-08-12 US disclosed
EP-0788511-B1 CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY FUJISAWA PHARMACEUTICAL CO (JP) 2002-12-11 EP disclosed
US-6265536-B1 MICROBIOCIDE AND FUNGICIDE WHICH IS INHIBITOR OF BETA-1,3-GLUCAN SYNTHASE; TREATMENT OF PNEUMOCYSTIS CARINII INFECTION FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-07-24 US disclosed
EP-1086193-A1 MONOSTABLE FERROELECTRIC ACTIVE MATRIX DISPLAY Aventis Research & Technologies GmbH & Co. KG. (DE) 2001-03-28 EP disclosed
US-6107458-A FUNGICIDE WHICH IS BETA-1,3-GLYCAN SYNTHASE INHIBITOR; FOR PROPHYLAXIS AND TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS LIKE PNEUMONIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-08-22 US disclosed
WO-1999064537-A1 MONOSTABLE FERROELECTRIC ACTIVE MATRIX DISPLAY AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) 1999-12-16 WO disclosed
US-5741438-A Optically active biphenyl derivative, process for preparation thereof, liquid crystal composition containing the same as an effective component, and liquid crystal element using the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1998-04-21 US disclosed
WO-1996011210-A1 CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-04-18 WO disclosed
US-5382380-A Ferroelectric material for displays KANTO KAGAKU KABUSHIKI KAISHA (JP) 1995-01-17 US disclosed
EP-0395390-B1 Optically active biphenyl derivative, process for preparation thereof, liquid crystal composition containing the same as effective component, and liquid crystal element using the same SUMITOMO CHEMICAL CO (JP) 1994-09-28 EP disclosed
EP-0360042-B1 p-Terphenyl derivatives and liquid crystalline compositions KANTO KAGAKU (JP) 1993-11-03 EP disclosed
EP-0395390-A1 Optically active biphenyl derivative, process for preparation thereof, liquid crystal composition containing the same as effective component, and liquid crystal element using the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1990-10-31 EP disclosed
EP-0360042-A1 p-Terphenyl derivatives and liquid crystalline compositions KANTO KAGAKU KABUSHIKI KAISHA (JP) 1990-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015223-A1 Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto HTR5A, HTR2A, HTR3A HSD17B10 3795/4885TSHR 114/4885RARB 1589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.